KPTIKaryopharm Therapeutics IncRunning, no new patients
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
1Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
6 insiders sold shares within a month
Since May 14, 2026 · was worth 10, fading over time
Worry score1
Score over time
- Stage
- Phase 3
- Patients
- 257 (final count)
- Started
- Apr 18, 2023
- Main results expected
- May 22, 2026
- Fully finished
- Jan 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Investigator assessed Progression Free Survival (PFS) per RECIST v1.1
Measured over: From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05611931 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC